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Background
Ideally, decisions on the value of health technologies
should be based on evidence from well-conducted clini-
cal trials that assess clinically important final patient-
relevant outcomes, such as mortality or impaired quality
of life. Pressure to reduce the delay in the availability of
technologies to patients has led to an increased reliance
on the use of surrogate outcomes [1]. A key tenant of
surrogate outcomes is unbiased quantification of the
predictive treatment effect on the final patient-relevant
clinical outcomes. This study compares the treatment
outcome of trials that use a surrogate versus a final
patient-relevant primary outcome.
Materials and methods
We searched for all randomized controlled trials (RCTs)
published in JAMA, NEJM, Lancet, BMJ, PLoS Medicine
and Annals of Internal Medicine in 2005 and 2006 [2].
We distinguished between trials that used a surrogate or
a patient-relevant primary outcome. An outcome was
defined as a surrogate if it did not directly measure
“how a patient feels, functions, or survives” [3] or was
judged to be a substitute and predictive of a final out-
come [1]. We excluded non-RCTs, composite (of both
surrogate and final) outcomes, economic evaluations
and non-interventional technologies. Surrogate and final
outcome trials were matched on patient population,
intervention, journal and year of publication. In this pre-
liminary analysis we compare the two groups of trials
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Table 1 Characteristics of included surrogate and final
trials.
Surrogate Trials (N=138)
N(%)
Final Trials (N=132)
N(%)
Intervention clinical
area
Cardiovascular 31(22) 31(23)
Endocrinology 11(8) 4(3)
Gastrology/
hepatology
11(8) 11(8)
Infectious disease 28(20) 28(21)
Nephrology/
urology
4(3) 4(3)
Neurology 2(1) 3(2)
Obstetrics 5(4) 5(4)
Oncology 4(3) 4(3)
Other 36(26) 36(27)
Pulmunology 6(4) 6(5)
Population clinical
area
Cardiovascular 34(25) 31(23)
Endocrinology 14(10) 9(7)
Gastrology/
hepatology
9(7) 10(8)
Infectious disease 21(15) 21(16)
Nephrology/
urology
2(1) 5(4)
Neurology 2(1) 2(2)
Obstetrics 7(5) 8(6)
Oncology 4(3) 4(3)
Other 36(26) 36(27)
Pulmunology 9(7) 6(5)
Journal
Annals 14(10) 10(8)
BMJ 11(8) 14(11)
JAMA 31(22) 31(23)
Lancet 28(20) 28(21)
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their outcome results.
Results
Of the 639 citations identified by our searches, we
included 138 trials that used a primary surrogate out-
come (‘surrogate trials’)a n d1 3 2t r i a l st h a tu s e daf i n a l
patient-relevant outcomes (‘final trials’). Table 1 sum-
marises the trial characteristics used for matching.
Other trial characteristics also appeared to be well
balanced except for the length of follow-up (i.e. more
studies with follow up <30 days and >1 year for final
trials).
Conclusions
This preliminary analysis supports our initial hypothesis
that the use of surrogate outcomes is more likely to lead
statistically significant treatment effects than patient-
relevant primary outcomes. We are currently undertak-
ing additional analysis using actual effect sizes in meta-
analytic/meta-regression framework. These results have
important implications for payers faced with making
coverage decisions on the effectiveness and cost-effec-
tiveness of new treatments based on surrogate rather
than final clinical trials data.
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Table 2 Comparison of outcome results.
Surrogate Trials
(N=138) N (%)
Final Trials
(N=132) N (%)
P-
value
a
Study outcome
b 0.006
c
Positive 49 (36) 41 (31)
Negative 5 (4) 4 (3)
Neutral 32 (23) 65 (49)
Risk of bias
Statement of ITT 95 (69) 106 (80) 0.031
Automated
sequence generation
82 (59) 93 (70) 0.058
Allocation
concealment
96 (70) 97 (63) 0.476
Blinding/Placebo 72 (52) 60 (45) 0.27
aChi-square test, unless otherwise specified.
b‘positive’: treatment group superior to control (P≤0.05); ‘negative’, control
group superior to treatment (P≤0.05); ‘neutral’, treatment and control
indifferent, P>0.05).
cFisher’s exact test. Multiple-interventions trials are excluded from this
comparison.
Table 1 Characteristics of included surrogate and final
trials. (Continued)
NEJM 51(37) 49(37)
PLoS 3(2) -
Year
2005 64(46) 63(48)
2006 74(54) 69(52)
Surrogate trials were less likely to have adequate evidence of randomisation
sequence generation and adopt the ITT principle. We also found clear
evidence that final trials were more likely to observe a non-statistically
significant (‘neutral’) treatment effect than surrogate trials (49% vs 23%)
(Table 2).
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